​

CRISPR Therapeutics (CRSP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CRSP Stock Forecast

CRISPR Therapeutics (CRSP) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $75.71, with a high of $100.00 and a low of $59.00. This represents a 79.32% increase from the last price of $42.22.

$35 $48 $61 $74 $87 $100 High: $100 Avg: $75.71 Low: $59 Last Closed Price: $42.22

CRSP Stock Rating

CRISPR Therapeutics stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (66.67%), 3 Hold (25.00%), 1 Sell (8.33%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 1 3 8 Strong Sell Sell Hold Buy Strong Buy

CRSP Price Target Upside V Benchmarks

TypeNameUpside
StockCRISPR Therapeutics79.32%
SectorHealthcare Stocks 25.00%
IndustryBiotech Stocks 63.52%

Price Target Trends

1M3M12M
# Anlaysts138
Avg Price Target$65.00$75.67$72.75
Last Closing Price$42.22$42.22$42.22
Upside/Downside53.96%79.23%72.31%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25511112-29
Jan, 25411112-28
Dec, 24411112129
Nov, 24411112129
Oct, 24611123133
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 03, 2025Mitchell KapoorH.C. Wainwright$65.00$40.0062.50%53.96%
Nov 06, 2024Jay OlsonOppenheimer$95.00$49.5191.88%125.01%
Nov 05, 2024Rick BienkowskiLeerink Partners$67.00$50.3633.04%58.69%
Aug 12, 2024Joon LeeTruist Financial$100.00$46.55114.82%136.85%
Aug 06, 2024Gil BlumNeedham$84.00$50.1167.63%98.96%
Aug 06, 2024Benjamin BurnettStifel Nicolaus$59.00$50.0117.98%39.74%
Aug 06, 2024Luca IssiRBC Capital$60.00$50.1319.69%42.11%
May 09, 2024Jack AllenRobert W. Baird$52.00$53.29-2.42%23.16%
Nov 23, 2022Citigroup$63.00$55.7213.07%49.22%
Aug 09, 2022Geulah LivshitsChardan Capital$79.30$81.39-2.57%87.83%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024Leerink PartnersOutperformOutperformhold
Aug 06, 2024Cowen & Co.SellSellhold
Aug 06, 2024NeedhamBuyBuyhold
Aug 06, 2024RBC CapitalSector PerformSector Performhold
Jun 17, 2024Piper SandlerOverweightOverweighthold
Apr 18, 2024CitigroupBuyBuyhold
Feb 15, 2024Wolfe ResearchPeer Performinitialise
Dec 11, 2023JMP SecuritiesMarket OutperformMarket Outperformhold
Oct 17, 2023Cantor FitzgeraldOverweightNeutraldowngrade
Aug 17, 2023CitigroupNeutralBuyupgrade

Financial Forecast

EPS Forecast

$-50 $-31 $-12 $7 $26 $45 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.29$4.97$-8.36$-1.94-----
Avg Forecast$-5.02$4.88$-9.09$-2.92$-5.17$-5.07$-3.12$-1.00$1.71
High Forecast$-45.76$-0.68$-36.12$-4.16$-6.53$-6.60$-7.69$-5.76$-0.47
Low Forecast$0.70$44.49$2.49$-1.60$-4.73$-3.01$8.56$9.76$7.17
Surprise %5.38%1.84%-8.03%-33.56%-----

Revenue Forecast

$0 $1B $3B $4B $6B $7B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$543.00K$913.08M$436.00K$370.00M-----
Avg Forecast$2.32M$903.86M$6.14M$293.21M$11.13M$118.69M$506.62M$1.02B$1.69B
High Forecast$287.31K$112.01M$122.50K$173.24M$1.21M$2.49M$496.61M$1.01B$35.48M
Low Forecast$16.78M$6.54B$20.20M$377.05M$36.07M$410.38M$516.62M$1.04B$5.85B
Surprise %-76.58%1.02%-92.90%26.19%-----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-348.87M$377.66M$-650.17M$-153.61M-----
Avg Forecast$-282.52M$338.20M$-603.01M$-153.61M$-445.92M$-448.97M$-262.09M$-119.23M$135.47M
High Forecast$-339.03M$121.81M$-723.61M$-184.33M$-517.43M$-522.52M$-609.51M$-456.49M$-36.95M
Low Forecast$-226.02M$554.59M$-482.41M$-122.89M$-374.41M$-238.06M$678.45M$773.32M$568.30M
Surprise %23.48%11.67%7.82%------

CRSP Forecast FAQ

Is CRISPR Therapeutics stock a buy?

CRISPR Therapeutics stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that CRISPR Therapeutics is a favorable investment for most analysts.

What is CRISPR Therapeutics's price target?

CRISPR Therapeutics's price target, set by 12 Wall Street analysts, averages $75.71 over the next 12 months. The price target range spans from $59 at the low end to $100 at the high end, suggesting a potential 79.32% change from the previous closing price of $42.22.

How does CRISPR Therapeutics stock forecast compare to its benchmarks?

CRISPR Therapeutics's stock forecast shows a 79.32% upside, outperforming the average forecast for the healthcare stocks sector (25.00%) and outperforming the biotech stocks industry (63.52%).

What is the breakdown of analyst ratings for CRISPR Therapeutics over the past three months?

  • February 2025: 17.24% Strong Buy, 37.93% Buy, 37.93% Hold, 6.90% Sell, 0% Strong Sell.
  • January 2025: 14.29% Strong Buy, 39.29% Buy, 39.29% Hold, 7.14% Sell, 0% Strong Sell.
  • December 2024: 13.79% Strong Buy, 37.93% Buy, 37.93% Hold, 6.90% Sell, 3.45% Strong Sell.

What is CRISPR Therapeutics’s EPS forecast?

CRISPR Therapeutics's average annual EPS forecast for its fiscal year ending in December is $-5.17 for 2024, a 166.49% increase from the reported $-1.94 in 2023. The prediction for 2025 is $-5.07, $-3.12 for 2026, $-1 for 2027, and $1.71 for 2028.

What is CRISPR Therapeutics’s revenue forecast?

CRISPR Therapeutics's average annual revenue forecast for its fiscal year ending in December is $11.13M for 2024, a -96.99% decrease from the reported $370M in 2023. The forecast for 2025 is $118.69M, $506.62M for 2026, $1.02B for 2027, and $1.69B for 2028.

What is CRISPR Therapeutics’s net income forecast?

For its fiscal year ending in December, CRISPR Therapeutics's average annual net income forecast is $-446M for 2024, reflecting an 190.29% increase from the reported $-154M in 2023. The projection for 2025 is $-449M, $-262M for 2026, $-119M for 2027, and $135.47M for 2028.